<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Strategic Allocation: Conservative Fund A Class — News on 6ix</title>
    <link>https://6ix.com/company/strategic-allocation-conservative-fund-a-class</link>
    <description>Latest news and press releases for Strategic Allocation: Conservative Fund A Class on 6ix.</description>
    <language>en-us</language>
    <lastBuildDate>Tue, 21 Apr 2026 04:00:00 GMT</lastBuildDate>
    <generator>6ix RSS</generator>
    <atom:link href="https://6ix.com/rss/company/strategic-allocation-conservative-fund-a-class" rel="self" type="application/rss+xml" />
    <item>
      <title>Getty Realty Corp. Announces Regular Quarterly Cash Dividend</title>
      <link>https://6ix.com/company/strategic-allocation-conservative-fund-a-class/news/getty-realty-corp-announces-regular-quarterly-cash-dividend</link>
      <guid isPermaLink="true">https://6ix.com/company/strategic-allocation-conservative-fund-a-class/news/getty-realty-corp-announces-regular-quarterly-cash-dividend</guid>
      <pubDate>Tue, 21 Apr 2026 04:00:00 GMT</pubDate>
      <description>NEW YORK, April 21, 2026 (GLOBE NEWSWIRE) -- Getty Realty Corp. (NYSE: GTY) (“Getty” or the “Company”), a net lease REIT focused on convenience and automotive</description>
    </item>
    <item>
      <title>Black Diamond Therapeutics Announces Oral Presentation of Silevertinib Phase 2 Data in Frontline EGFRm NSCLC Patients at the 2026 ASCO Annual Meeting</title>
      <link>https://6ix.com/company/strategic-allocation-conservative-fund-a-class/news/black-diamond-therapeutics-announces-oral-presentation-of-silevertinib-phase-2-data-in-frontline-egfrm-nsclc-patients-at-the-2026-asco-annual-meeting-6</link>
      <guid isPermaLink="true">https://6ix.com/company/strategic-allocation-conservative-fund-a-class/news/black-diamond-therapeutics-announces-oral-presentation-of-silevertinib-phase-2-data-in-frontline-egfrm-nsclc-patients-at-the-2026-asco-annual-meeting-6</guid>
      <pubDate>Tue, 21 Apr 2026 04:00:00 GMT</pubDate>
      <description>Poster also to be presented on the Phase 2 data of silevertinib in recurrent EGFRm NSCLC patients Trial-in-progress poster to be presented on the randomized</description>
    </item>
  </channel>
</rss>